CD8A and neoplasm: reported that in preclinical models, liver metastases induce systemic loss of tumor-specific CD8+ T cells and abrogate the efficacy of immunotherapy, a phenomenon that mirrors systemic T-cell dysfunction and decreases the treatment response observed in patients with liver metastases (39).